Clindamycin Phosphate
FDA-approved product (injectable, injection), marketed as Cleocin, Cleocin Phosphate, Cleocin Phosphate In Dextrose 5% In Plastic Container and 12 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Abdominal abscess
- Abscess
- Acne
- Bacterial disease
- Bacterial vaginosis
- Empyema
- Endometritis
- Female reproductive system disease
- Infection
- Irritable bowel syndrome
- Lung Abscess
- Osteomyelitis
- Parametritis
- Peritonitis
- Pneumonia
- Pseudomembranous enterocolitis
- and 3 more
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Antiinfectives for treatment of acne; Antibiotics; Lincosamides
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC D10AF01; WHO ATC J01FF01; WHO ATC G01AA10
Repurposing investigation
Clindamycin Phosphate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae19.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Clindamycin Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PlecanatideExisting use: Constipation52.2% AI-predicted activityagainst K. pneumoniae15 registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma51.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome50.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency49.5% AI-predicted activityagainst K. pneumoniae7 registered studies
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease49.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Codeine SulfateExisting use: Cough, Drug dependence, Migraine disorder and 2 more48.8% AI-predicted activityagainst K. pneumoniae23 registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more48.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis48.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LypressinExisting use: Vasopressin and analogues48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more48.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection47.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies
NCT01722708 · start 2012-11-01
Registered record
- Registry ID
- NCT01722708
- Conditions
- Abnormal Vaginal Flora; Clindamycin Vs Metronidazole; High Risk Pregnancies for Preterm Labor
- Interventions
- Clindamycin; Metronidazole
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2012-11-01
- Completion
- 2025-12-30
- Enrolment
- 166
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbnormal Vaginal Flora; Clindamycin Vs Metronidazole; High Risk Pregnancies for Preterm LaborInterventionClindamycin; MetronidazolePhaseNot applicableRegistry statusCompletedStudy Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris
NCT01769235 · start 2012-11
Registered record
- Registry ID
- NCT01769235
- Conditions
- Acne Vulgaris
- Interventions
- Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%; Acanya® Gel, 1.2%/2.5%; Vehicle of test product
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-11
- Completion
- 2013-12
- Enrolment
- 1,215
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventionClindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%; Acanya® Gel, 1.2%/2.5%; Vehicle of test productPhasePhase 1Registry statusCompletedEfficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection
NCT01757236 · start 2012-10
Registered record
- Registry ID
- NCT01757236
- Conditions
- Hip Prosthetic Joint Infection
- Interventions
- VANCOMYCIN; CEFTRIAXONE; CLINDAMYCIN; SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE); FLUOROQUINOLONE; LINEZOLID; RIFAMPIN
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2012-10
- Completion
- 2016-04
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHip Prosthetic Joint InfectionInterventionVANCOMYCIN; CEFTRIAXONE; CLINDAMYCIN; SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE) +3 morePhasePhase 2Registry statusUnknownEvaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris
NCT01788384 · start 2012-07
Registered record
- Registry ID
- NCT01788384
- Conditions
- Acne Vulgaris
- Interventions
- Clindamycin Phosphate / Benzoyl Peroxide Gel; Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%; Placebo (Vehicle Gel)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-07
- Completion
- 2012-12
- Enrolment
- 708
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventionClindamycin Phosphate / Benzoyl Peroxide Gel; Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%; Placebo (Vehicle Gel)PhasePhase 3Registry statusCompletedStudy STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
NCT01445301 · start 2011-09-27
Registered record
- Registry ID
- NCT01445301
- Conditions
- Acne Vulgaris
- Interventions
- GSK2585823(CLDM 1%-BPO 3% gel); CLDM 1% gel twice daily
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-09-27
- Completion
- 2012-08-02
- Enrolment
- 800
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventionGSK2585823(CLDM 1%-BPO 3% gel); CLDM 1% gel twice dailyPhasePhase 3Registry statusCompletedThe Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery
NCT01912651 · start 2011-09-22
Registered record
- Registry ID
- NCT01912651
- Conditions
- Facial Defect
- Interventions
- cephalexin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-09-22
- Completion
- 2025-11-07
- Enrolment
- 236
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFacial DefectInterventioncephalexinPhasePhase 4Registry statusCompletedClinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)
NCT02366884 · start 2011-07-26
Registered record
- Registry ID
- NCT02366884
- Conditions
- Neoplasms
- Interventions
- Anti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal Agents
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2011-07-26
- Completion
- 2023-12-31
- Enrolment
- 250
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeoplasmsInterventionAnti-Bacterial Agents; Anti-Fungal Agents; Anti-Protozoal AgentsPhasePhase 2Registry statusUnknownStudy STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects
NCT01400932 · start 2011-07
Registered record
- Registry ID
- NCT01400932
- Conditions
- Acne Vulgaris
- Interventions
- GI148512; vehicle gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-07
- Completion
- 2012-04
- Enrolment
- 360
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventionGI148512; vehicle gelPhasePhase 3Registry statusCompletedJapanese Phase 1 Study of GSK2585823
NCT01428466 · start 2010-11-18
Registered record
- Registry ID
- NCT01428466
- Conditions
- Acne Vulgaris
- Interventions
- GSK2585823; Benzoyl peroxide 3%; Benzoyl peroxide 5%; Vehicle
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-11-18
- Completion
- 2011-02-15
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventionGSK2585823; Benzoyl peroxide 3%; Benzoyl peroxide 5%; VehiclePhasePhase 1Registry statusCompletedAntibiotic Prophylaxis for Simple Hand Lacerations
NCT01155154 · start 2010-02
Registered record
- Registry ID
- NCT01155154
- Conditions
- Simple Hand Lacerations
- Interventions
- cephalexin; clindamycin; placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2010-02
- Completion
- 2012-02
- Enrolment
- 73
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSimple Hand LacerationsInterventioncephalexin; clindamycin; placeboPhaseNot applicableRegistry statusTerminatedCompare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
NCT01015638 · start 2009-08
Registered record
- Registry ID
- NCT01015638
- Conditions
- Acne Vulgaris
- Interventions
- Clindamycin and BPO 5% gel; Clindamycin phosphate and benzoyl peroxide 2.5% gel.
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-08
- Completion
- 2009-09
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventionClindamycin and BPO 5% gel; Clindamycin phosphate and benzoyl peroxide 2.5% gel.PhasePhase 4Registry statusCompletedA Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
NCT00964223 · start 2009-07
Registered record
- Registry ID
- NCT00964223
- Conditions
- Acne Vulgaris
- Interventions
- Clindamycin and benzoyl peroxide gel (Duac® Topical Gel); benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-07
- Completion
- 2009-11
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventionClindamycin and benzoyl peroxide gel (Duac® Topical Gel); benzoyl peroxide and adapalene gel (EPIDUO™ Gel)PhasePhase 4Registry statusCompletedStudy to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications
NCT00964366 · start 2009-07
Registered record
- Registry ID
- NCT00964366
- Conditions
- Acne Vulgaris
- Interventions
- clindamycin and benzoyl peroxide; Dapsone gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-07
- Completion
- 2009-08
- Enrolment
- 53
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventionclindamycin and benzoyl peroxide; Dapsone gelPhasePhase 4Registry statusCompletedSystemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
NCT00473083 · start 2009-01
Registered record
- Registry ID
- NCT00473083
- Conditions
- Rash
- Interventions
- Minocycline; Clindamycin 2% in hydrocortisone 1% lotion; Erlotinib; Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-01
- Completion
- 2013-08
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRashInterventionMinocycline; Clindamycin 2% in hydrocortisone 1% lotion; Erlotinib; Topical clindamycin 2%, triamcinolone acetonide 0.1% solnPhasePhase 2Registry statusCompletedW0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers
NCT01929278 · start 2008-12-08
Registered record
- Registry ID
- NCT01929278
- Conditions
- Acne Vulgaris
- Interventions
- CT Gel (clindamycin 1% and tretinoin 0.025%); Vehicle gel patch; Blank patch
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-12-08
- Completion
- 2008-12-19
- Enrolment
- 37
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcne VulgarisInterventionCT Gel (clindamycin 1% and tretinoin 0.025%); Vehicle gel patch; Blank patchPhasePhase 1Registry statusCompleted